1. Home
  2. RARE vs IGT Comparison

RARE vs IGT Comparison

Compare RARE & IGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RARE
  • IGT
  • Stock Information
  • Founded
  • RARE 2010
  • IGT 2014
  • Country
  • RARE United States
  • IGT United Kingdom
  • Employees
  • RARE N/A
  • IGT N/A
  • Industry
  • RARE Biotechnology: Pharmaceutical Preparations
  • IGT Services-Misc. Amusement & Recreation
  • Sector
  • RARE Health Care
  • IGT Consumer Discretionary
  • Exchange
  • RARE Nasdaq
  • IGT Nasdaq
  • Market Cap
  • RARE 3.3B
  • IGT 3.2B
  • IPO Year
  • RARE 2014
  • IGT N/A
  • Fundamental
  • Price
  • RARE $37.17
  • IGT $14.58
  • Analyst Decision
  • RARE Strong Buy
  • IGT Strong Buy
  • Analyst Count
  • RARE 17
  • IGT 4
  • Target Price
  • RARE $92.29
  • IGT $23.25
  • AVG Volume (30 Days)
  • RARE 974.0K
  • IGT 2.7M
  • Earning Date
  • RARE 07-31-2025
  • IGT 07-29-2025
  • Dividend Yield
  • RARE N/A
  • IGT 5.48%
  • EPS Growth
  • RARE N/A
  • IGT 44.55
  • EPS
  • RARE N/A
  • IGT 1.62
  • Revenue
  • RARE $590,689,000.00
  • IGT $2,434,000,000.00
  • Revenue This Year
  • RARE $18.94
  • IGT $2.11
  • Revenue Next Year
  • RARE $28.93
  • IGT $1.83
  • P/E Ratio
  • RARE N/A
  • IGT $8.92
  • Revenue Growth
  • RARE 33.46
  • IGT 14.38
  • 52 Week Low
  • RARE $29.59
  • IGT $13.81
  • 52 Week High
  • RARE $60.37
  • IGT $24.13
  • Technical
  • Relative Strength Index (RSI)
  • RARE 55.64
  • IGT 35.94
  • Support Level
  • RARE $35.73
  • IGT $14.27
  • Resistance Level
  • RARE $36.22
  • IGT $14.76
  • Average True Range (ATR)
  • RARE 1.37
  • IGT 0.44
  • MACD
  • RARE 0.25
  • IGT -0.11
  • Stochastic Oscillator
  • RARE 90.54
  • IGT 9.87

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

About IGT International Game Technology

International Game Technology PLC is a gaming company that delivers entertaining and responsible gaming experiences for players across all channels. The company operates into single segment namely Gaming & Digital. Geographically, it derives a majority of revenue from the United States. The company also has its presence in Italy, Rest of Europe and Other countries.

Share on Social Networks: